These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 37884415)

  • 21. Immunogenicity and Safety of a Tetravalent Recombinant Subunit Dengue Vaccine in Adults Previously Vaccinated with a Live Attenuated Tetravalent Dengue Vaccine: Results of a Phase-I Randomized Clinical Trial.
    Durbin AP; Pierce KK; Kirkpatrick BD; Grier P; Sabundayo BP; He H; Sausser M; Russell AF; Martin J; Hyatt D; Cook M; Sachs JR; Lee AW; Wang L; Coller BA; Whitehead SS
    Am J Trop Med Hyg; 2020 Aug; 103(2):855-863. PubMed ID: 32394880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Immunogenicity of an AS03
    Lin L; Lyke KE; Koren M; Jarman RG; Eckels KH; Lepine E; McArthur MA; Currier JR; Friberg H; Moris P; Keiser PB; De La Barrera R; Vaughn DW; Paris RM; Thomas SJ; Schmidt AC
    Am J Trop Med Hyg; 2020 Jul; 103(1):132-141. PubMed ID: 32342848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate.
    Jackson LA; Rupp R; Papadimitriou A; Wallace D; Raanan M; Moss KJ
    Vaccine; 2018 Jun; 36(27):3976-3983. PubMed ID: 29789238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life.
    Patel SS; Winkle P; Faccin A; Nordio F; LeFevre I; Tsoukas CG
    Hum Vaccin Immunother; 2023 Aug; 19(2):2254964. PubMed ID: 37846724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.
    Strezova A; Godeaux O; Aggarwal N; Leroux-Roels G; Lopez-Fauqued M; Van Damme P; Vanden Abeele C; Vastiau I; Heineman TC; Lal H
    Vaccine; 2017 Dec; 35(48 Pt B):6700-6706. PubMed ID: 29079101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study.
    Rupp R; Luckasen GJ; Kirstein JL; Osorio JE; Santangelo JD; Raanan M; Smith MK; Wallace D; Gordon GS; Stinchcomb DT
    Vaccine; 2015 Nov; 33(46):6351-9. PubMed ID: 26384447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.
    Sirivichayakul C; Barranco-Santana EA; Esquilin-Rivera I; Oh HM; Raanan M; Sariol CA; Shek LP; Simasathien S; Smith MK; Velez ID; Wallace D; Gordon GS; Stinchcomb DT
    J Infect Dis; 2016 May; 213(10):1562-72. PubMed ID: 26704612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
    Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lot-to-lot consistency, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults: A randomized, double-blind, phase IV trial.
    Zhu D; Hu Y; Jiang Z; Yang T; Chu K; Zhang H; Hu J; Meng X; Tan Z; Wu J; Lian X; Li C; Pan H
    Hum Vaccin Immunother; 2022 Nov; 18(6):2135929. PubMed ID: 36441137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults.
    Russell KL; Rupp RE; Morales-Ramirez JO; Diaz-Perez C; Andrews CP; Lee AW; Finn TS; Cox KS; Falk Russell A; Schaller MM; Martin JC; Hyatt DM; Gozlan-Kelner S; Bili A; Coller BG
    Hum Vaccin Immunother; 2022 Nov; 18(5):2046960. PubMed ID: 35290152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA.
    Dayan GH; Thakur M; Boaz M; Johnson C
    Vaccine; 2013 Oct; 31(44):5047-54. PubMed ID: 24021313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination.
    López-Medina E; Biswal S; Saez-Llorens X; Borja-Tabora C; Bravo L; Sirivichayakul C; Vargas LM; Alera MT; Velásquez H; Reynales H; Rivera L; Watanaveeradej V; Rodriguez-Arenales EJ; Yu D; Espinoza F; Dietze R; Fernando LK; Wickramasinghe P; Duarte Moreira E; Fernando AD; Gunasekera D; Luz K; da Cunha RV; Tricou V; Rauscher M; Liu M; LeFevre I; Wallace D; Kosalaraksa P; Borkowski A
    J Infect Dis; 2022 May; 225(9):1521-1532. PubMed ID: 33319249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials.
    Tran NH; Chansinghakul D; Chong CY; Low CY; Shek LP; Luong CQ; Fargo C; Wartel TA; Sun S; Skipetrova A; Bouckenooghe A
    Hum Vaccin Immunother; 2019; 15(10):2315-2327. PubMed ID: 30724660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE).
    Simon JK; Staerke NB; Hemming-Harlo M; Layle S; Dagan R; Shekar T; Pedley A; Jumes P; Tamms G; Sterling T; Musey L; Buchwald UK;
    Vaccine; 2022 Feb; 40(9):1342-1351. PubMed ID: 35039194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
    Ishola D; Manno D; Afolabi MO; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Leyssen M; Greenwood B; Douoguih M; Leigh B; Watson-Jones D;
    Lancet Infect Dis; 2022 Jan; 22(1):97-109. PubMed ID: 34529963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three-year Efficacy and Safety of Takeda's Dengue Vaccine Candidate (TAK-003).
    Rivera L; Biswal S; Sáez-Llorens X; Reynales H; López-Medina E; Borja-Tabora C; Bravo L; Sirivichayakul C; Kosalaraksa P; Martinez Vargas L; Yu D; Watanaveeradej V; Espinoza F; Dietze R; Fernando L; Wickramasinghe P; Duarte MoreiraJr E; Fernando AD; Gunasekera D; Luz K; Venâncioda Cunha R; Rauscher M; Zent O; Liu M; Hoffman E; LeFevre I; Tricou V; Wallace D; Alera M; Borkowski A
    Clin Infect Dis; 2022 Aug; 75(1):107-117. PubMed ID: 34606595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of a single dose, live-attenuated 'tetravalent dengue vaccine' in healthy Indian adults; a randomized, double-blind, placebo controlled phase I/II trial.
    Mohanty L; Prabhu M; Kumar Mishra A; Purty AJ; Kanungo R; Ghosh G; Prahan Kumar R; Newton Raj A; Bhushan S; Kumar Jangir M; Gupta A; Bhakri A
    Vaccine X; 2022 Apr; 10():100142. PubMed ID: 35252836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.
    George SL; Wong MA; Dube TJ; Boroughs KL; Stovall JL; Luy BE; Haller AA; Osorio JE; Eggemeyer LM; Irby-Moore S; Frey SE; Huang CY; Stinchcomb DT
    J Infect Dis; 2015 Oct; 212(7):1032-41. PubMed ID: 25791116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil.
    Dayan GH; Garbes P; Noriega F; Izoton de Sadovsky AD; Rodrigues PM; Giuberti C; Dietze R
    Am J Trop Med Hyg; 2013 Dec; 89(6):1058-1065. PubMed ID: 24189367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
    Kumar Rai G; Saluja T; Chaudhary S; Tamrakar D; Kanodia P; Giri BR; Shrestha R; Uranw S; Kim DR; Yang JS; Park IY; Kyung SE; Vemula S; Reddy E J; Kim B; Gupta BP; Jo SK; Ryu JH; Park HK; Shin JH; Lee Y; Kim H; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
    Lancet Infect Dis; 2022 Apr; 22(4):529-540. PubMed ID: 34942090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.